SAB Biotherapeutics (NASDAQ:SABS – Get Free Report)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a research report issued to clients and investors on Tuesday, Benzinga reports. They presently have a $6.00 target price on the stock. HC Wainwright’s target price suggests a potential upside of 27.66% from the company’s current price.
Separately, Chardan Capital reiterated a “buy” rating and issued a $25.00 price objective on shares of SAB Biotherapeutics in a report on Tuesday.
Read Our Latest Analysis on SABS
SAB Biotherapeutics Trading Up 2.0 %
Institutional Trading of SAB Biotherapeutics
Several large investors have recently modified their holdings of the business. Vanguard Group Inc. boosted its position in SAB Biotherapeutics by 2.0% during the 4th quarter. Vanguard Group Inc. now owns 996,132 shares of the company’s stock valued at $685,000 after acquiring an additional 19,194 shares in the last quarter. BVF Inc. IL bought a new stake in SAB Biotherapeutics during the 4th quarter valued at approximately $6,310,000. Pathstone Holdings LLC bought a new stake in SAB Biotherapeutics during the 4th quarter valued at approximately $348,000. Commodore Capital LP bought a new stake in SAB Biotherapeutics during the 4th quarter valued at approximately $1,259,000. Finally, Kestra Advisory Services LLC boosted its position in SAB Biotherapeutics by 319.0% during the 4th quarter. Kestra Advisory Services LLC now owns 88,000 shares of the company’s stock valued at $60,000 after acquiring an additional 67,000 shares in the last quarter. 7.82% of the stock is owned by institutional investors.
SAB Biotherapeutics Company Profile
SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.
Read More
- Five stocks we like better than SAB Biotherapeutics
- 3 Grocery Stocks That Are Proving They Are Still Essential
- Silicon Motion Proves That AI in Motion Stays in Motion
- Profitably Trade Stocks at 52-Week Highs
- Undervalued UnitedHealth Group Won’t Be For Long
- What is a buyback in stocks? A comprehensive guide for investors
- The 5 Stocks Most Sold By Insiders This Year
Receive News & Ratings for SAB Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAB Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.